The Pharma companies focusing on oncology has been emerging in market with greater needs of people suffering from Cancer. The sales of oncology drugs gradually increasing with diseases. The top oncology companies are now developing more advanced- effective- and tolerable drugs to improve treatment outcomes and the patient experience. Roche proved to be on top 10 list of Oncology companies. Our team at PharmaShots has compiled a list of top 10 oncology companies based on their 2018 total revenue.

10. ABBVIE

Total Revenue: $32.73B                                                                 Total Employees: ~30-000   

Oncology Segment Revenue: $3.93B                                       Pharma Segment Revenue: $32.73B

Founded Year: 1900                                                                     Headquarter: Illinois- United States                                                                              

Market Cap: ~$114.73B                                                                 Stock Exchange: NYSE

AbbVie is a global- research-based biopharmaceutical company that develops therapies majorly for Chronic Autoimmune Diseases- Oncology- Virology with additional targets like cystic fibrosis and women's health. In Apr'18- AbbVie initiated P-III trial for the combination therapy of Imbruvica + Venclexta vs chlorambucil plus Gazyva (obinutuzumab) to treat 1L chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). AbbVie's key product Humira (adalimumab) is a biologic therapy and is approved in the US- Canada- Mexico- and EU. In Dec'18- AbbVie pact a deal with Lupin to develop novel therapies for cancer.

9. ELI LILLY

Total Revenue: $24.55B                                                                Total Employees: ~38-680

Oncology Segment Revenue: $4.26B                                     Pharma Segment Revenue: $22.93B

Founded Year: 1901                                                                        Headquarter: Indiana- United States 

Market Cap: ~$112.52B                                                                Stock Exchange: NYSE

Eli Lilly and Company is a global pharmaceutical firm focused on delivering therapies in two divisions Human Pharmaceutical products and Animal Health products. The pharmaceutical portfolio offers products for Cardiovascular- Endocrinology- Immunology- Neuroscience- and Oncology. In Q4'18- Lilly's Verzenio was approved in Japan and EU for metastatic breast cancer. In 2018 Lilly expanded its oncology portfolio by acquisition of Loxo Oncology.

8. ASTRAZENECA

Total Revenue: $22.09B                                                                Total Employees: ~50-000                                          

Oncology Segment Revenue: $6.02B                                       Pharma Segment Revenue: $21.04B

Founded Year: 1999                                                                        Headquarter: Cambridge- United Kingdom

Market Cap: ~$51.5B                                                                     Stock Exchange: NYSE

AstraZeneca is a global- biopharmaceutical company focusing on Oncology- Respiratory- Neurology- Autoimmune and other therapy areas. In Dec'18 AstraZeneca and Merck's Lynparza (olaparib) received FDA's approval as 1L treatment for BRCA-Mutated Advanced Ovarian Cancer. In early 2018 AstraZeneca granted Innate Pharma the commercialization rights for Lumoxiti in the US and EU. The company also has the PD molecule Imfinzi- an approved product for bladder and lung cancer.

7. PFIZER

Total Revenue: $53.64B                                                                Total Employees: ~92-400

Oncology Segment Revenue: $7.20B                                      Pharma Segment Revenue: $53.64B  

Founded Year: 1849                                                                        Headquarter: New York- United States

Market Cap: ~$232.96B                                                                Stock Exchange: NYSE                         

Pfizer is a research-based- global biopharmaceutical company having a vast portfolio including Oncology- Medicines- Vaccine and other health care products for the prevention & treatment of untreated diseases. In 2018- Pfizer's leading Oncology drugs Vizimpro (dacomitinib)- Talzenna (talazoparib) and Lorbrena (lorlatinib) received FDA?s approvals for NSCLC- Breast Cancer and ALK+ NSCLC respectively.

6. MERCK & CO.

Total Revenue: $42.29B                                                                 Total Employees: ~69-000

Oncology Segment Revenue: $8.24B                                      Pharma Segment Revenue: $42.29B

Founded Year: 1891                                                                        Headquarter: New Jersey- United States

Market Cap: ~$205.15B                                                               Stock Exchange: NYSE

Merck & Co. is a global health care company delivering innovative health care products with its Prescription medicines- Oncology drugs- Vaccines- Biologic therapies and Animal Health care products. In Mar'18- Merck and Eisai signed worldwide collaboration for the co-development and co-commercialization of Eisai's Lenvima. Merck has numerous successful therapies in its portfolio including Keytruda with net sales of $7.17B in 2018 and has 900+ trials for Keytruda including 600+ in oncology

5. JOHNSON & JOHNSON

Total Revenue: $81.58B                                                                Total Employees: ~135-100

Oncology Segment Revenue: $9.84B                                     Pharma Segment Revenue: $40.73B

Founded Year: 1887                                                                        Headquarter: New Jersey- United States

Market Cap: ~$350.76B                                                                Stock Exchange: NYSE

Johnson & Johnson (J&J) is an American multinational medical device- pharmaceutical- and consumer packaged goods manufacturing company. The pharmaceutical department of the company focuses on Immunology- Oncology- Infectious Diseases and Vaccines- Neuroscience- Cardiovascular and Metabolism and the medical device sector is focused on Orthopedics and Cardiovascular Disease solutions. Johnson's Oncology portfolio generated total revenue of $9.8B in 2018 exceeding 35.6% to 2017.

4. BRISTOL-MYERS SQUIBB

Total Revenue: $22.56B                                                                Total Employees: ~23-300

Oncology Segment Revenue: $10.31B                                  Pharma Segment Revenue: $22.56B

Founded Year: 1989                                                                      Headquarter: New York- United States

Market Cap: ~$75.05B                                                                  Stock Exchange: NYSE

Bristol-Myers Squibb is an American pharmaceutical company focused on Oncology- Cardiovascular- Immuno-Science- and Fibrosis. Its blockbusters drug Opdivo (nivolumab) used for cancer has generated sales of $6.7B in 2018. In Dec'18 the company collaborated with Vedanta Biosciences for the development of combination therapies for Advanced or Metastatic Cancers. BMS acquired Celgene in 2019 to strengthen its portfolio of Oncology- Immunology- Inflammation- and Cardiology. 

3. NOVARTIS

Total Revenue: $51.9B                                                                   Total Employees: ~125-161 Employees    

Oncology Segment Revenue: $13.42B                                    Pharma Segment Revenue: $42.3B

Founded Year: 1996                                                                        Headquarter: Basel- Switzerland

Market Cap: ~$216.96B                                                              Stock Exchange: SIX Swiss Exchange- NYSE

Novartis is a multinational group of companies specializing in the research- development- manufacture and marketing drugs which is divided into two categories: Novartis Oncology and Novartis Pharmaceuticals. The Oncology portfolio offers drugs in areas of Cancer and Hematologic disorders. While the pharma portfolio offers in Ophthalmology- Neuroscience- Immunology- Hepatology including Dermatology and Respiratory. In Dec'18 the company acquired Endocyte to strengthen its portfolio of nuclear medicine and radioligand therapy used for treating cancer.

2. CELGENE

Total Revenue: $15.42B                                                                     Total Employees: ~16-962

Oncology Segment Revenue: $13.65B                                       Pharma Segment Revenue: $15.26B               

Founded Year: 1986                                                                            Headquarter: New Jersey- United States

Market Cap: ~$66.70B                                                                       Stock Exchange: NASDAQ

Celgene is an integrated global biopharmaceutical company focused on developing therapies in Oncology- Immunology- Hematology- and Inflammatory Diseases. Celgene's one of the leading Cancer drug Revlimid is in P-III trials including Otezla- is evaluated in patients with r/r follicular or marginal zone lymphoma & Behcet's disease respectively. Additionally- in 2018 Celgene expanded its collaboration with Dragonfly for Solid and Hematological Cancers. In 2019- Celgene is acquired by BMS for $74B. 

1. ROCHE

Total Revenue: $56.91B                                                                 Total Employees: ~92-400

Oncology Segment Revenue: $26.06B                                    Pharma Segment Revenue: $44.10B 

Founded Year: 1849                                                                        Headquarter: New York- United States  

Market Cap: ~$226.50B                                                                 Stock Exchange: NYSE

Roche Holding AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Roche?s Oncology portfolio is currently focusing on Breast- Bladder- Cervical- Ovarian- Liver- etc. In 2018- Roche achieved good growth in both the divisions and delivered therapies like Xofluza (baloxavir marboxil) for influenza and targets serious diseases like cancer- multiple sclerosis- & hemophilia.

*Companies listed above are based on oncology segment revenue. Celgene and BMS
oncology segment revenue has been taken prior to acquisition.